# A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations

> **NCT07288580** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Euhearing Therapeutics Co., Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

## Interventions

- **DRUG:** EHT102 Injection

## Key facts

- **NCT ID:** NCT07288580
- **Lead sponsor:** Shanghai Euhearing Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-02
- **Primary completion:** 2028-06-30
- **Final completion:** 2033-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07288580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07288580, "A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07288580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*